Table 2. Distribution of expenditure among different dry eye treatment groups.

	Quarterly Expenditure in 2008 (US$) (Mean±SD)	Quarterly Expenditure in 2009 (US$) (Mean±SD)	Expenditure per Patient Episode (US$)
Phamacological Treatments
Meibomian gland disease therapy	29509.52±1936.56	30638.12±681.97	12.68
Preservative free lubricant eye drops	155461.90±6739.84	166837.49±5176.30	37.10
Preserved lubricant eye drops	92848.48±7311.95	76398.98±3837.25	12.45
Lubricant ointments and gels	59384.31±9477.15	49793.29±2769.97	19.96
Cyclosporin eye drops	37747.65±4262.05	43131.68±4060.93	143.09
Oral Supplements	4063.325†	10704.16±4828.84	80.27
Non Phamacological Treatments/Procedures
Punctum Cautery	122.60±80.89	215.11±101.97	25.49
Punctum plug	2501.12±573.38	1634.14±655.65	87.98
Tarsorrhaphy	790.44±220.76	846.46±436.12	72.75

^†Oral supplements were only available in pharmacy from last quarter of 2008.